Pep2Tango Therapeutics, Inc.

POTOMAC, MD · Founded 2021 · Biotech · Private

Multi-agonist peptide therapeutics targeting GLP-1, GIP, and glucagon receptors for weight loss and metabolic improvement

Claim this profile

Follows are private to you and power your alerts

Updated · pep2tango.com

Sector
Biotech
Headquarters
POTOMAC, MD
Founded
2021
Latest Form D
$16.7M, Nov 2024
Total capital
$16.7M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$16.7M
1 Form D · last Nov 2024
23 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
7 pending

Capital timeline

2024FEDERAL ↑EQUITY ↓Cumulative $16.7M1st Form D$16.7M
2024FEDERAL ↑EQUITY ↓Cumulative $16.7M1st Form D$16.7M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$16.7M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Carlo RizzutoDirectorNamed in SEC Form D filings
  • Cristina RondinoneExecutive Officer, DirectorNamed in SEC Form D filings
  • Mickey KimDirectorNamed in SEC Form D filings
  • Soumitra GhoshDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 7
  • PendingCompositions Including Multi-agonist Peptides And Methods Of Manufacture And UseUSPTOApplication 18352077
  • PendingCompositions Including Multi-agonist Peptides And Methods Of Manufacture And UseUSPTOApplication 17812993
  • PendingCompositions Including Multi-agonist Peptides And Methods Of Manufacture And UseUSPTOApplication PCTUS2023070152
Show all 7 patent records
  • Compositions Including Multi-agonist Peptides And Methods Of Manufacture And UseFeb 22, 2024 · Application 18352077Pending
  • Compositions Including Multi-agonist Peptides And Methods Of Manufacture And UseJun 29, 2023 · Application 17812993Pending
  • Compositions Including Multi-agonist Peptides And Methods Of Manufacture And UseApplication PCTUS2023070152Pending
  • Compositions Including Multi-agonist Peptides And Methods Of Manufacture And UseApplication 63389769Pending
  • Compositions Including Multi-agonist Peptides And Methods Of Manufacture And UseApplication 63222747Pending
  • Compositions Including Multi-agonist Peptides And Methods Of Manufacture And UseApplication PCTUS2022073793Pending
  • Compositions Including Multi-agonist Peptides And Methods Of Manufacture And UseApplication 63435723Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .